Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -3.26 is 2154% below its 5-year average of 0.16, near the low end of its 5-year range (-3.26–2.57).
As of the fiscal period ended Tuesday, June 30, 2026. 2768.66% below its 12-month average of -0.11.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -3.26.
DEBT TO EQUITY RATIO
-3.26
DEBT TO EQUITY RATIO AVG TTM
-0.11
DEBT TO EQUITY RATIO AVG 3Y
0.23
DEBT TO EQUITY RATIO AVG 5Y
0.16
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-2768.66%
CURRENT VS 3Y AVG
-1506.42%
CURRENT VS 5Y AVG
-2153.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-3061.46%
vs the sector median at left
Tenon Medical, Inc.
Market Cap
$1.84M
Debt to Equity Ratio
-3.26
TTM Avg
-0.11
3Y Avg
0.23
5Y Avg
0.16
Market Cap
$1.83M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.81M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.13
5Y Avg
0.18
Market Cap
$1.88M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.09
5Y Avg
0.07
Market Cap
$1.88M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$2.14M
Debt to Equity Ratio
N/A
TTM Avg
2.52
3Y Avg
1.40
5Y Avg
1.14
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tenon Medical, Inc. (TNON) | $1.84M | -3.26 | -0.11 | 0.23 | 0.16 |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | 11.82 | 2.34 | 1.37 | 0.96 |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | 0.00 | 0.00 | 0.13 | 0.18 |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | 0.00 | 0.00 | 0.09 | 0.07 |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | 0.00 | 0.00 | 0.03 | 0.03 |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | 0.00 | 0.00 | 0.00 | 0.00 |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | 0.18 | 0.11 | 0.06 | 0.04 |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | 2.52 | 1.40 | 1.14 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | 0.02 | N/A | N/A | N/A |
Debt/Equity
-3.26
Current Ratio
0.58
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -3.26 |
| 2026-03-31 | 2.57 |
| 2025-12-31 | 0.03 |
| 2025-09-30 | 0.05 |
| 2025-06-30 | 0.04 |
| 2025-03-31 | 0.04 |
| 2024-12-31 | 0.07 |
| 2024-09-30 | 0.06 |
| 2024-06-30 | 0.67 |
| 2024-03-31 | 0.17 |
| 2023-12-31 | 2.39 |
| 2023-09-30 | 0.30 |
| 2023-06-30 | 0.89 |
| 2023-03-31 | 0.35 |
| 2022-12-31 | 0.15 |
| 2022-09-30 | 0.07 |
| 2022-06-30 | 0.07 |
| 2022-03-31 | -0.65 |
| 2021-12-31 | -0.71 |
| 2021-09-30 | -2.28 |
| 2021-06-30 | -2.25 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | -0.18 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
